Literature DB >> 3377769

Characterization of partially purified cytosolic protein-tyrosine kinase from porcine spleen.

K Sakai1, S Nakamura, K Sada, T Kobayashi, H Uno, H Yamamura.   

Abstract

Biochemical properties of a cytosolic protein-tyrosine kinase (CPTK-40) partially purified from porcine spleen were characterized and compared with p40 kinase, a cytosolic protein-tyrosine kinase from bovine thymus. When CPTK-40 was incubated with MnCl2 and (gamma-32P)ATP, only a phosphoprotein with a molecular weight of 40 kilodalton was observed. CPTK-40 efficiently phosphorylated tubulin with the rate of 0.5 nmol/min/mg. Unlike p40 kinase, casein was also a substrate for CPTK-40. Among various divalent cations tested, Co2+, Mn2+ and Mg2+ were effective metal ions for the enzyme activity. Ca2+ could also serve as a divalent cation for the activity although the rate was low. These results suggest that CPTK-40 is similar but not identical to p40 kinase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377769     DOI: 10.1016/s0006-291x(88)80401-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Purification of catalytic domain of rat spleen p72syk kinase and its phosphorylation and activation by protein kinase C.

Authors:  P Borowski; M Heiland; L Kornetzky; S Medem; R Laufs
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

2.  Partial purification and characterization of the lck protein-tyrosine kinase from bovine thymus.

Authors:  Q M Wang; P R Srinivas; M L Harrison; R L Geahlen
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

3.  Biochemical characteristics of cytosolic and particulate forms of protein tyrosine kinases from N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinoma.

Authors:  A K Srivastava; J C Chiasson; J L Chiasson; A Lacroix; L Windisch
Journal:  Mol Cell Biochem       Date:  1991-07-24       Impact factor: 3.396

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.

Authors:  Ryosuke Matsukane; Kimitaka Suetsugu; Takeshi Hirota; Ichiro Ieiri
Journal:  Clin Pharmacokinet       Date:  2022-07-04       Impact factor: 5.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.